RxDoctor Payments Data

Gilberto Gastell, MD

Internal Medicine · Union City, NJNPI 1942200472

Payments from drug & device makers

$537in general payments, 2019–2025

Across 37 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$133
  • Arbor Pharmaceuticals, Inc.$117
  • Sumitomo Pharma America, Inc.$94
  • Pfizer$61
  • AbbVie$43
  • AstraZeneca$32
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$48190%
  • Education$5610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$537 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$437,276
Medicare patients
672
Services billed
5,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide358$380,876
EliquisApixaban374$332,498
JanuviaSitagliptin Phosphate242$262,035
OzempicSemaglutide183$248,489
FarxigaDapagliflozin Propanediol228$236,348
JardianceEmpagliflozin193$215,758
Repatha SureclickEvolocumab203$203,480
VascepaIcosapent Ethyl397$190,941
Diclofenac Sodium534$173,281
LinzessLinaclotide213$162,721
GemtesaVibegron137$106,938
Breo ElliptaFluticasone/Vilanterol147$88,958
XareltoRivaroxaban81$83,608
ProliaDenosumab40$66,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$63,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$18$426,075386 claims
PfizerEliquis$61$332,498374 claims
AstraZenecaFarxiga, Brilinta$32$254,975246 claims
AbbVieLinzess, Creon, Namzaric, Restasis$43$253,409318 claims
Sumitomo Pharma America, Inc.Gemtesa$94$106,938137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Union City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →